The pharmaceutical company Endo Health Solutions recently settled a set of a qui tam (whistleblower) lawsuits for $193 million dollars. The first suit was filed in 2005, by a sales representative who started working at Endo in 2002.
The whistleblowers alleged that Endo violated Federal law by marketing Lidoderm for unapproved uses, including for low back pain, diabetic neuropathy and carpal tunnel syndrome. The Federal Food, Drug and Cosmetic Act (FDCA) prohibits this practice, known as “off-label marketing” because the prescribing information ...
continue reading...